PDF herunterladen
Semin Hear 2019; 40(02): 108-121
DOI: 10.1055/s-0039-1684041
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Review of Cisplatin-Associated Ototoxicity

Jessica Paken
1   Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
,
Cyril D. Govender
1   Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
,
Mershen Pillay
1   Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
,
Vikash Sewram
2   African Cancer Institute
3   Division of Health Systems and Public Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
26. April 2019 (online)

Auch verfügbar auf
   Artikel einzeln kaufen Lizenzen und Reprints
Zoom Image

Abstract

Cisplatin, an effective antineoplastic drug used in the treatment of many cancers, has ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing loss. It is therefore important for health care professionals managing these patients to be aware of cisplatin's ototoxic properties and its clinical signs to identify patients at risk of developing a hearing impairment. Eighty-five English peer-reviewed articles and two books, from January 1975 to July 2015, were identified from PubMed, ScienceDirect, and EBSCOhost. An overview of cisplatin-associated ototoxicity, namely its clinical features, incidence rates, molecular and cellular mechanisms, and risk factors, is presented in this article. This review further highlights the importance of a team-based approach to complement an audiological monitoring program in reducing any further loss in the quality of life of affected patients, as there is currently no otoprotective agent routinely recommended for the prevention of cisplatin-associated ototoxicity.

Keywords

cisplatin - ototoxicity - hearing loss - ototoxicity monitoring program - cancer - otoprotectant

Disclosures

The study is supported by the Medical Research Council of South Africa in terms of the National Health Scholarship Program provided for this purpose by the National Department of Health. The study also received financial support from Oticon Foundation and the University of Kwazulu-Natal. This paper has been presented at the ENT/SAAA/SASLHA Congress 2015 in South Africa, Audiology Australia National Conference 2016, and the World Congress of Audiology 2016.


This paper is a summarized version of Jessica Paken, Cyril D. Govender, Mershen Pillay, and Vikash Sewram, “Cisplatin-Associated Ototoxicity: A Review for the Health Professional,” Journal of Toxicology, Vol. 2016, Article ID 1809394, 13 pages, 2016. https://doi.org/10.1155/2016/1809394.